Article Text

Download PDFPDF

Endogenous, local, vascular endothelial growth factor production in patients with chronic total coronary artery occlusions: further evidence for its role in angiogenesis
Free
  1. H El-Gendi1,
  2. A G Violaris1,
  3. R Foale1,
  4. H S Sharma2,
  5. D J Sheridan1
  1. 1Division of National Heart and Lung Institute, St Mary's Hospital, Academic Cardiology Unit, London, UK
  2. 2Erasmus University Medical Center, Rotterdam, The Netherlands
  1. Correspondence to:
    Dr AG Violaris, Academic Cardiology Unit, 10th Floor QEQM Wing, St Mary's Hospital, Paddington W2 1NY, UK;
    d.sheridan{at}ic.ac.uk

Statistics from Altmetric.com

Growth factors are currently emerging as a new therapeutic tool in coronary heart disease.1 Endogenous expression patterns of a number of angiogenic growth factors have been described in the chronically ischaemic and collateralised hearts.2 Through their proven experimental angiogenic effect, the administration of vascular endothelial growth factor (VEGF)3 and basic fibroblast growth factor (bFGF)1 have been explored as a means of increasing the degree of collateralisation in patients with end stage coronary heart disease. Questions remain however on the optimal dose, duration of administration, and monitoring of these agents1–3 as well as on the magnitude of risk posed by angiogenic cytokine treatment for accelerating atherosclerosis,4,5 partly because of the paucity of data on local growth factor concentrations and changes in living man. Patients with total coronary …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.